Anti-CD20 antibody - Pipeline Insight, 2021
This report can be delivered to the clients within 72 Hours
DelveInsight’s, “Anti-CD20 antibody – Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Anti-CD20 antibody pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Anti-CD20 antibody: Overview
CD20 is a 33- to 37-kDa non-glycosylated phosphoprotein expressed on the surface of mature undifferentiated B-cells. Expression starts at the pre–B-cell stage, and persists until terminal differentiation into plasma cells. This pattern, together with consistent and high levels of expression of CD20 on malignant B-cells, makes CD20 a therapeutic target. CD20 protein consists of four hydrophobic transmembrane domains, one intracellular and two extracellular domains (large and small loops) with both N- and C- termini residing within the cytosol. Expression of CD20 antigen by the most of transformed B cells is believed to be the driving force for targeting this molecule by using anti-CD20 monoclonal antibodies. Anti-CD20 monoclonal antibodies (mAbs) are used to achieve B cell depletion, and were initially developed to treat B cell proliferative disorders, including non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Use of anti-CD20 therapy is vastly practiced to treat diseases with a high expression of CD20 antigen. Anti-CD20 antibodies are one of the most successful and effective antibodies which have employed in treatment of a wide range of diseases including cancer and immune related disorders.
'Anti-CD20 antibody - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Anti-CD20 antibody pipeline landscape is provided which includes the disease overview and Anti-CD20 antibody treatment guidelines. The assessment part of the report embraces, in depth Anti-CD20 antibody commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Anti-CD20 antibody collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Anti-CD20 antibody report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Anti-CD20 antibody Emerging Drugs
Further product details are provided in the report
Anti-CD20 antibody: Therapeutic Assessment
This segment of the report provides insights about the different Anti-CD20 antibody drugs segregated based on following parameters that define the scope of the report, such as:
Anti-CD20 antibody: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Anti-CD20 antibody therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anti-CD20 antibody drugs.
Anti-CD20 antibody Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Anti-CD20 antibody – Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Anti-CD20 antibody pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Anti-CD20 antibody: Overview
CD20 is a 33- to 37-kDa non-glycosylated phosphoprotein expressed on the surface of mature undifferentiated B-cells. Expression starts at the pre–B-cell stage, and persists until terminal differentiation into plasma cells. This pattern, together with consistent and high levels of expression of CD20 on malignant B-cells, makes CD20 a therapeutic target. CD20 protein consists of four hydrophobic transmembrane domains, one intracellular and two extracellular domains (large and small loops) with both N- and C- termini residing within the cytosol. Expression of CD20 antigen by the most of transformed B cells is believed to be the driving force for targeting this molecule by using anti-CD20 monoclonal antibodies. Anti-CD20 monoclonal antibodies (mAbs) are used to achieve B cell depletion, and were initially developed to treat B cell proliferative disorders, including non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Use of anti-CD20 therapy is vastly practiced to treat diseases with a high expression of CD20 antigen. Anti-CD20 antibodies are one of the most successful and effective antibodies which have employed in treatment of a wide range of diseases including cancer and immune related disorders.
'Anti-CD20 antibody - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Anti-CD20 antibody pipeline landscape is provided which includes the disease overview and Anti-CD20 antibody treatment guidelines. The assessment part of the report embraces, in depth Anti-CD20 antibody commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Anti-CD20 antibody collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Anti-CD20 antibody R&D. The therapies under development are focused on novel approaches to treat/improve Anti-CD20 antibody.
This segment of the Anti-CD20 antibody report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Anti-CD20 antibody Emerging Drugs
- Ublituximab: TG therapeutics
- Glofitamab: Roche
Further product details are provided in the report
Anti-CD20 antibody: Therapeutic Assessment
This segment of the report provides insights about the different Anti-CD20 antibody drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Anti-CD20 antibody
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Anti-CD20 antibody: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Anti-CD20 antibody therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anti-CD20 antibody drugs.
Anti-CD20 antibody Report Insights
- Anti-CD20 antibody Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Anti-CD20 antibody drugs?
- How many Anti-CD20 antibody drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Anti-CD20 antibody?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Anti-CD20 antibody therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Anti-CD20 antibody and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Anti-CD20 antibody: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Anti-CD20 antibody – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Anti-CD20 antibody companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Anti-CD20 antibody Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Preregistration)
Comparative Analysis
Ublituximab: TG therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
Odronextamab: Regeneron Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early stage products (Phase I)
Comparative Analysis
IGM 2323: IGM Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Anti-CD20 antibody Key Companies
Anti-CD20 antibody Key Products
Anti-CD20 antibody- Unmet Needs
Anti-CD20 antibody- Market Drivers and Barriers
Anti-CD20 antibody- Future Perspectives and Conclusion
Anti-CD20 antibody Analyst Views
Anti-CD20 antibody Key Companies
Appendix
Executive Summary
Anti-CD20 antibody: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Anti-CD20 antibody – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Anti-CD20 antibody companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Anti-CD20 antibody Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Preregistration)
Comparative Analysis
Ublituximab: TG therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
Odronextamab: Regeneron Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early stage products (Phase I)
Comparative Analysis
IGM 2323: IGM Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Anti-CD20 antibody Key Companies
Anti-CD20 antibody Key Products
Anti-CD20 antibody- Unmet Needs
Anti-CD20 antibody- Market Drivers and Barriers
Anti-CD20 antibody- Future Perspectives and Conclusion
Anti-CD20 antibody Analyst Views
Anti-CD20 antibody Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Anti-CD20 antibody
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Anti-CD20 antibody
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Anti-CD20 antibody
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Anti-CD20 antibody
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
